The Latest Breaking News from SVB Leerink

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Edwards Lifesciences Corp (NYSE:EW) posted a Q1 adjusted EPS of $0.60, compared to $0.54 posted a year ago and beating the consensus of $0.57. Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion. Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's…

Benzinga · Apr 27, 2022

SVB Leerink Maintains Market Perform Rating for Myovant Sciences, Lowers Price Target To $12

SVB Leerink has decided to maintain its Market Perform rating of Myovant Sciences (NYSE:MYOV) and lower its price target from $19.00 to $12.00. Shares of Myovant Sciences are trading up 8.08% over the last 24 hours, at $11.23 per share.

Benzinga · Apr 13, 2022

SVB Leerink Maintains Market Perform Rating for Rubius Therapeutics, Lowers Price Target To $3

SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Benzinga · Apr 11, 2022